What will the price of Mobotinib be in 2025? Where can I buy this medicine?

Mobotinib is a prescription drug specially designed to treat patients with EGFR-positive non-small cell lung cancer (NSCLC). It effectively prevents the growth and reproduction of cancer cells by blocking the abnormal EGFR protein produced by exon 20 insertion mutations. For patients with EGFR-positive NSCLC, abnormal epidermal growth factor receptor (EGFR) on the surface of their cancer cells can lead to excessive cell proliferation, and mobotinib targets this mechanism to exert its therapeutic effect.

In terms of price, the original drug of Mobotinib has always maintained a high level, with a box selling for about tens of thousands of yuan, which has brought considerable financial pressure to many patients. However, in recent years, with the successive launch of generic drugs, this situation has improved significantly. For example, in the Laotian market, the generic drug of Mobotinib produced by Lucius Pharmaceuticals and Daxiong Pharmaceutical is priced at more than 3,000 yuan. Compared with the original drug, this price greatly reduces the financial burden on patients. In the Bangladeshi market, the price of the generic drug of Mobotinib produced by Ziskar Pharmaceuticals is even lower, about more than 2,000 yuan, which also provides patients with a more economical choice.

However, it should be noted that the original drug of Mobotinib has been withdrawn from the market in China, and it is difficult for patients to purchase it through regular domestic channels. So, for patients who need this drug, how can they get it? One possible way is to consult reputable and qualified overseas medical institutions. These institutions can usually provide formal drug sources and purchase channels to help patients solve medication problems. However, patients must exercise caution when choosing these institutions and ensure that the institutions they choose have relevant legal qualifications and good reputation to avoid unnecessary risks and losses.

In general, Mobotinib is an effective drug against EGFR-positive NSCLC. Although the price of the original drug is higher, with the launch of generic drugs, patients have more and more economical options. Due to the delisting of the original drug from the domestic market, patients may consider obtaining the drug through overseas medical institutions, but they must choose carefully to ensure the safety and effectiveness of the drug.

References:

https://www.medicalnewstoday.com/articles/drugs-exkivity#about